AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
14.55
-0.45 (-3.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
AnaptysBio Employees
AnaptysBio had 117 employees as of December 31, 2023. The number of employees increased by 21 or 21.88% compared to the previous year.
Employees
117
Change (1Y)
21
Growth (1Y)
21.88%
Revenue / Employee
$488,650
Profits / Employee
-$1,415,880
Market Cap
442.74M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
InnovAge Holding | 2,350 |
Ginkgo Bioworks Holdings | 1,218 |
MeiraGTx Holdings | 425 |
UroGen Pharma | 201 |
Kodiak Sciences | 111 |
Alumis | 109 |
Theravance Biopharma | 99 |
PureTech Health | 90 |
ANAB News
- 10 days ago - AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data - Benzinga
- 10 days ago - AnaptysBio to abandon eczema drug development after mid-stage trial failure - Reuters
- 10 days ago - AnaptysBio abandons eczema drug development after mid-stage trial failure - Reuters
- 10 days ago - Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - GlobeNewsWire
- 6 weeks ago - Anaptys Announces Participation in November and December Investor Conferences - GlobeNewsWire
- 6 weeks ago - Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Anaptys Announces Participation in September Investor Conferences - GlobeNewsWire
- 4 months ago - AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point - Seeking Alpha